Semaglutide for Weight Loss: The STEP Trial Program

The STEP Program Overview

Novo Nordisk’s Semaglutide Treatment Effect in People with obesity (STEP) program is a series of randomized, double-blind, placebo-controlled trials that evaluated semaglutide 2.4 mg for chronic weight management. The trials enrolled a total of roughly 5,000 adults across five pivotal studies, each designed to answer a different clinical question about the drug’s efficacy and durability.

All STEP trials used the same dose: semaglutide 2.4 mg administered subcutaneously once weekly, preceded by an 16-week dose escalation period starting at 0.25 mg. This slow titration was designed to minimize gastrointestinal side effects. For a full pharmacological profile, see our semaglutide research page.

STEP 1: The Pivotal Obesity Trial

STEP 1 (Wilding et al., NEJM, 2021) was the registration trial. It enrolled 1,961 adults with BMI 30 or above (or 27 with at least one weight-related condition), excluding those with diabetes. The treatment period was 68 weeks.

Participants on semaglutide lost a mean of 14.9% of their body weight, compared to 2.4% for placebo. The difference was both statistically significant and clinically meaningful by every standard metric used in obesity research.

One-third of participants crossed the 20% threshold. Before semaglutide, that level of weight loss was essentially only achievable through bariatric surgery. STEP 1 redefined what was pharmacologically possible.

STEP 2: Obesity with Type 2 Diabetes

STEP 2 (Davies et al., Lancet, 2021) asked a critical question: does the effect hold in people with Type 2 diabetes? Diabetes is well known to make weight loss more difficult through mechanisms including insulin resistance, medication-induced weight gain, and metabolic adaptation.

The answer was yes, but with a reduced magnitude. Participants on semaglutide 2.4 mg lost 9.6% of body weight over 68 weeks, compared to 3.4% for placebo. The trial also tested a 1.0 mg dose, which produced 7.0% weight loss. HbA1c dropped by 1.6 percentage points in the 2.4 mg group, a clinically significant improvement in glycemic control on top of the weight benefit.

STEP 2 confirmed that semaglutide produces meaningful weight loss in diabetes populations, though the magnitude is roughly two-thirds of what non-diabetic participants achieve.

STEP 3: Adding Behavioral Therapy

STEP 3 (Wadden et al., JAMA, 2021) combined semaglutide 2.4 mg with an intensive behavioral therapy program: 30 individual counseling sessions on diet, exercise, and behavior change. The comparison was semaglutide plus behavioral therapy versus placebo plus behavioral therapy.

The result was 16.0% weight loss in the semaglutide group versus 5.7% in the placebo group. The behavioral therapy component did add value. The placebo arm lost substantially more than in STEP 1 (5.7% vs 2.4%), demonstrating that structured counseling is effective. But when stacked on top of semaglutide, the incremental gain was modest: 16.0% versus 14.9% in STEP 1.

STEP 4: What Happens When You Stop

STEP 4 (Rubino et al., JAMA, 2021) is arguably the most informative trial in the program from a clinical perspective. All participants received semaglutide 2.4 mg for an initial 20-week run-in period. Those who responded (losing at least 5%) were then randomized to either continue semaglutide or switch to placebo for an additional 48 weeks.

Participants who continued semaglutide went on to lose 17.4% total body weight. Those switched to placebo regained approximately two-thirds of the weight they had lost during the run-in, ending at roughly 5% below their original baseline.

STEP 5: Two-Year Durability

STEP 5 (Garvey et al., Nature Medicine, 2022) extended the treatment window to 104 weeks, the longest duration in the STEP program. Participants lost 15.2% of body weight at two years, with the weight loss plateau occurring around week 60 and remaining stable through week 104.

This is important because it addresses the concern that GLP-1 receptor agonists might lose efficacy over time through receptor desensitization or metabolic adaptation. The STEP 5 data suggest that semaglutide’s effect is durable over at least two years of continuous use, without evidence of progressive tolerance.

The SELECT Trial: Cardiovascular Outcomes

SELECT (Lincoff et al., NEJM, 2023) was not part of the STEP series but represents the most significant extension of semaglutide’s evidence base. It enrolled 17,604 adults aged 45 or older with established cardiovascular disease and obesity (BMI 27 or above) but without diabetes.

The primary endpoint was a composite of cardiovascular death, non-fatal heart attack, or non-fatal stroke (3-point MACE). Semaglutide reduced this endpoint by 20% over a mean follow-up of 39.8 months. The result was statistically significant and consistent across subgroups.

SELECT was the first completed cardiovascular outcomes trial for any weight loss medication in a non-diabetic population. It fundamentally changed how semaglutide is viewed: not just as a weight loss drug, but as a cardiovascular risk reduction agent in people with obesity.

Side Effects Across the STEP Program

GI adverse events were the most common side effects across all STEP trials. They followed a consistent pattern: highest incidence during dose escalation, declining substantially after reaching the maintenance dose, and rarely leading to discontinuation.

The STEP trials characterized the tolerability of semaglutide, but the drug’s full safety profile extends beyond the gastrointestinal events seen most often in those studies. Semaglutide carries an FDA boxed warning, the agency’s most serious warning category, for thyroid C-cell tumors. In rodent studies it caused dose-dependent and treatment-duration-dependent thyroid C-cell tumors, including medullary thyroid carcinoma, and whether it causes such tumors in humans is not known. It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

How Semaglutide Compares to the Next Generation

The STEP program established semaglutide as the standard against which newer compounds are measured. Tirzepatide, the dual GIP/GLP-1 agonist from Eli Lilly, has since demonstrated 22.5% weight loss in the SURMOUNT-1 trial, exceeding what semaglutide achieved in STEP 1. The margin is significant: roughly 50% more weight loss from the dual-receptor approach.

Novo Nordisk’s own pipeline includes cagrilintide/semaglutide (CagriSema), which combines semaglutide with an amylin analog for a different dual-mechanism approach. Early Phase 2 data suggest it may narrow or close the gap with tirzepatide.

The bottom line from the STEP program is straightforward. Semaglutide 2.4 mg produces roughly 15% weight loss, maintains it for at least two years, and reduces cardiovascular risk by 20% in people with established heart disease. It is the most thoroughly validated pharmaceutical weight loss agent in history. The question now is not whether it works, but whether newer agents can do better, and by how much.

For full molecular and pharmacological details, see our semaglutide research profile. For a head-to-head comparison with the leading competitor, read our tirzepatide analysis.

This article is for educational and informational purposes only. It is not intended as medical advice and should not be used to diagnose, treat, or prevent any condition. Always consult with a qualified healthcare professional before making health-related decisions. Clinical trial data referenced here is sourced from peer-reviewed publications and may not reflect the most current findings.